Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Metastasis Review

• Publication date

  2014-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10555-013-9482-0PMID 24414227PMCID PMC4096322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

  2014cited by this paper
• Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

  2013cited by this paper
• The role of BRCA1 and BRCA2 in prostate cancer.

  2013cited by this paper
• Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts

  2013cited by this paper
• The decline and fall of the IGF‐I receptor

  2013cited by this paper
• Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

  2013cited by this paper
• β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c‐Jun amino terminal kinase 1

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 Prostate Cancer Xenografts

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

  2013cited by this paper
• A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer

  2012cited by this paper
• KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation.

  2012cited by this paper
• Global Methylation Analysis Identifies PITX2 as an Upstream Regulator of the Androgen Receptor and IGF-I Receptor Genes in Prostate Cancer

  2012cited by this paper
• The role of BRCA1 and BRCA2 in prostate cancer.

  2012cited by this paper
• Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases.

  2012cited by this paper
• VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

  2012influential reference
• Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling.

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

  2012cited by this paper
• Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

  2011cited by this paper
• IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

  2011cited by this paper
• The type 1 insulin-like growth factor receptor and resistance to DACH1

  2011cited by this paper
• Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.

  2011cited by this paper
• Antisense oligonucleotide targeting of insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer

  2010influential reference
• The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

  2010cited by this paper
• The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.

  2010cited by this paper
• Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC).

  2010cited by this paper
• Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.

  2010cited by this paper
• AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

  2009cited by this paper
• Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

  2009cited by this paper
• Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor–Dependent Manner

  2009cited by this paper
• Implications of insulin‐like growth factor‐I for prostate cancer therapies

  2009cited by this paper
• A HIF‐1α‐dependent autocrine feedback loop promotes survival of serum‐deprived prostate cancer cells

  2009cited by this paper
• Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.

  2009cited by this paper
• The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.

  2008cited by this paper
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.

  2008cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008cited by this paper
• IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

  2007cited by this paper
• The role of the IGF system in cancer growth and metastasis: overview and recent insights.

  2007cited by this paper
• Role of Wnt/β‐catenin signaling pathway in epithelial‐mesenchymal transition of human prostate cancer induced by hypoxia‐inducible factor‐1α

  2007cited by this paper
• Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.

  2007cited by this paper
• An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer

  2007cited by this paper
• Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

  2007cited by this paper
• Insulin-Like Growth Factor (IGF) family and prostate cancer.

  2006cited by this paper
• Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors

  2006cited by this paper
• The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action.

  2006cited by this paper
• Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

  2006cited by this paper
• Interaction of IGF signaling and the androgen receptor in prostate cancer progression

  2006cited by this paper
• Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

  2005cited by this paper
• Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era

  2005cited by this paper
• Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

  2005cited by this paper
• Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer

  2005cited by this paper
• Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway

  2005cited by this paper
• Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin

  2005cited by this paper
• Spatial distribution of growth hormone receptor, insulin-like growth factor-I receptor and apoptotic chondrocytes during growth plate development.

  2005cited by this paper
• In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors

  2005cited by this paper
• Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.

  2004cited by this paper
• Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model

  2004cited by this paper
• The insulin-like growth factor system in advanced breast cancer.

  2004cited by this paper
• Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.

  2004cited by this paper
• High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.

  2004cited by this paper
• A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

  2003cited by this paper
• The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevance

  2003cited by this paper
• Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.

  2003cited by this paper
• The insulin-like growth factor system and cancer.

  2003cited by this paper
• The IGF‐1 receptor in cancer biology

  2003cited by this paper
• Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor.

  2003cited by this paper
• Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.

  2002cited by this paper
• Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.

  2002cited by this paper
• Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.

  2001cited by this paper
• Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

  2001cited by this paper
• Insulin-like growth factors and prostate cancer.

  2001cited by this paper
• Insulin-like Growth Factors and Prostate Cancer

  2001cited by this paper
• KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer

  2001cited by this paper
• In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).

  2001cited by this paper
• Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

  2001cited by this paper
• Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer

  2001cited by this paper
• Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression*

  2000cited by this paper
• Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

  2000cited by this paper
• Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice.

  2000cited by this paper
• Structure and function of the type 1 insulin-like growth factor receptor

  2000cited by this paper
• Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells.

  2000cited by this paper
• IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation

  2000cited by this paper
• HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

  2000cited by this paper
• The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

  2000cited by this paper
• Growth and Differentiation Signals by the Insulin-like Growth Factor 1 Receptor in Hemopoietic Cells Are Mediated through Different Pathways*

  1999cited by this paper
• The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

  1999cited by this paper
• Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

  1999cited by this paper
• Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

  1997cited by this paper
• Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells.

  1997cited by this paper
• Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer.

  1996cited by this paper
• The Nuclear Localization Sequences of the BRCA1 Protein Interact with the Importin-α Subunit of the Nuclear Transport Signal Receptor*

  1996cited by this paper
• BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner.

  1996cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain.

  1994cited by this paper

• Circulating tumour cells as a window into lethality in prostate cancer.

  2026cites this paper
• Proteome-wide association study of prostate cancer risk across populations.

  2025cites this paper
• Detection of Genome‐Wide IGF‐1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers

  2025cites this paper
• Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer

  2024cites this paper
• Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities

  2024cites this paper
• Poly-l-glutamic acid modification modulates the bio-nano interface of a therapeutic anti-IGF-1R antibody in prostate cancer.

  2023cites this paper
• miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targets

  2023cites this paper
• Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3′ untranslated region mutations

  2023cites this paper
• Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target

  2023cites this paper
• Brazilian Berry Extract Chemopreventive Action: Hormone Receptors as a Target to Mitigate Aging Prostatic Disorders.

  2022cites this paper
• Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

  2021cites this paper
• An affibody-conjugated nanoprobe for IGF-1R targeted cancer fluorescent and photoacoustic dual-modality imaging

  2021cites this paper
• The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

  2021cites this paper
• Parallel, High-Quality Proteomic and Targeted Metabolomic Quantification Using Laser Capture Microdissected Tissues.

  2021cites this paper
• Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer

  2021cites this paper
• Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer

  2021cites this paper
• Single-Walled Carbon Nanohorns as Promising Nanotube-Derived Delivery Systems to Treat Cancer

  2020cites this paper
• Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

  2020cites this paper
• AWARD NUMBER: W81XWH-15-1-0536 TITLE: TRAF4 and Castration-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR: Ping Yi CONTRACTING ORGANIZATION: Baylor College of Medicine

  2020cites this paper
• Expression of miR-148b-3p is correlated with overexpression of biomarkers in prostate cancer

  2020cites this paper
• Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis

  2019influential citation
• Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines

  2019cites this paper
• The impact of obesity and insulin resistance on thyroid cancer: A systematic review.

  2019cites this paper
• Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma

  2019cites this paper
• The conflicting role of E2F1 in prostate cancer: A matter of cell context or interpretational flexibility?

  2019cites this paper
• Cancer of Reproductive System: Receptors and Targeting Strategies

  2019cites this paper
• Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

  2019cites this paper
• Meningioma and Bone Hyperostosis: Expression of Bone Stimulating Factors and Review of the Literature.

  2018cites this paper
• TRAF4‐mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis

  2018cites this paper
• Caffeic acid phenethyl ester guards against benign prostate hypertrophy in rats: Role of IGF‐1R/protein kinase‐B (Akt)/β‐catenin signaling

  2018cites this paper
• IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway

  2018cites this paper
• Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma

  2018cites this paper
• Functional Roles of Matrix Metalloproteinases in Bone Metastatic Prostate Cancer

  2017cites this paper
• c‐Src, Insulin‐Like Growth Factor I Receptor, G‐Protein‐Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes

  2017cites this paper
• Prostate cancer and bone cell interactions : implications for metastatic growth and therapy

  2017cites this paper
• Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients

  2017cites this paper
• Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.

  2016cites this paper
• Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells

  2016cites this paper
• Molecular signaling involving intrinsically disordered proteins in prostate cancer

  2016cites this paper
• MicroRNA-497 targets hepatoma-derived growth factor and suppresses human prostate cancer cell motility.

  2016cites this paper
• Stabilising suppressor of cytokine signalling 3 (SOCS3) protein levels to limit neointimal hyperplasia

  2016cites this paper
• The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies

  2016cites this paper
• Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer.

  2016cites this paper
• SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

  2015cites this paper
• Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism

  2015cites this paper
• Growth hormone, insulin-like growth factor system and carcinogenesis.

  2015cites this paper
• Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis.

  2014cites this paper
• STUDIES ON THE MECHANISMS OF SORAFENIB-INDUCED CELL DEATH

  2014cites this paper